Green Earth Institute Co.,Ltd. · TSE:9212

Green Earth Institute Co.,Ltd — FY2026 Earnings Presentation

32 slides from Green Earth Institute Co.,Ltd's earnings presentation, Nov 16, 2026

  1. Slide 1: Full-Year FY2026 Financial Results Presentation & Mid- to Long-Term Vision Progress Report

    2026.11.16 From Petroleum To Bio. Bio-manufacturing changes the world. Full-Year FY2026 Financial Results Presentation & Mid- to Long-Term Vision Progress Report Toward Becoming an Integrated Industrial Platform Company for Bio-Manufacturing Green Earth Institute Co., Ltd. | Tokyo Stock Exchange Sta

  2. Slide 2: CEO Message: The Second Founding Has Begun

    02 / 32 CEO Message Recent Environment Surrounding Our Business and Our Response The “Second Founding” Has Begun For GEI, the fiscal year ended September 2026 was a year in which our R&D and commercialization efforts steadily delivered results and we stepped into our next stage of growth. The total

  3. Slide 3: Management indicator up 9 years in a row; ordinary profit positive 2 years

    03 / 32 M a n a g e m e n t I n d i c a t o r Tr e n d s Management indicator up 9 years in a row; ordinary profit positive 2 years in a row We position “Sales + Non-Operating Income” as our management indicator. The FY2027 earnings forecast plans for a 10th consecutive year of growth. (Million yen)

  4. Slide 4: Table of Contents

    04 / 32 Table of Contents This document combines the Financial Results Presentation and the Mid- to Long-Term Vision Progress Report, organized into the five sections below. 01 04 Executive Summary P. 0 5 Mid- to Long-Term Vision Progress P. 1 7 – 2 9 A review in three key points: • Overall pipeline

  5. Slide 5: Executive Summary: key messages in three points

    05 / 32 01 — Executive Summary The key messages of this document, summarized in three points Conclusions first: FY2026 results / FY2027 earnings forecast / Mid- to Long-Term Vision progress. POINT 01 FY2026 Results POINT 02 FY2027 Earnings Forecast POINT 03 Mid- to Long-Term Vision Progress Manageme

  6. Slide 6: Management indicator up for 9 consecutive years

    06 / 32 02 — FY2026 Results | Key Indicators Management indicator up for 9 consecutive years Results for FY2026 (October 2025 – September 2026): management indicator, its breakdown, and key profit indicators. Management Indicator Sales + Non-Operating Income 1,576 million yen YoY +27.8% 9 consecutiv

  7. Slide 7: Results exceeded the earnings forecast

    07 / 32 02 — FY2026 Results | Comparison with Earnings Forecast Results exceeded the earnings forecast ① Sales 2,000 (Million yen) ▍Sales: In line with forecast (+7 million yen) Cost of sales + Gross ✓ Sales were 1,042 million yen (+0.7% vs. forecast), and gross profit profit 1,500 was 438 million y

  8. Slide 8: Lower gross profit reflects absence of last year's license income

    08 / 32 02 — FY2026 Results | Comparison with Previous Year Lower gross profit reflects the absence of last year’s license income with no associated costs ① Sales 2,000 (Million yen) ▍Gross profit: −204 million yen YoY (642 → 438) Cost of sales + Gross ✓ The previous year included license income of

  9. Slide 9: Two-thirds of sales came from Development-Type Bio-Foundry

    09 / 32 02 — FY2026 Results | Sales Two-thirds of sales of 1,042 million yen came from Development-Type Bio- Foundry Full-year (October 2025 – September 2026) sales and share of sales by business. Development-Type Bio-Foundry Production-Type Bio-Foundry Technology Package 687million 6million yen (Sh

  10. Slide 10: About half of SG&A expenses of 753 million yen is R&D

    10 / 32 02 — FY2026 Results | SG&A Expenses About half of SG&A expenses of 753 million yen is R&D Full-year (October 2025 – September 2026) breakdown of SG&A expenses and share of SG&A. R&D Expenses Personnel Expenses Other 364million yen (Share of SG&A: 277million yen (Share of SG&A: 111million yen

  11. Slide 11: Structural changes by account

    11 / 32 02 — FY2026 Results | Balance Sheet Structural changes by account Balance sheet as of September 30, 2026 compared with the previous fiscal year-end. The three items marked ★ are the main drivers of change (explained on the next slide). (Unit: million yen) Account Title Sep. 30, 2025 Sep. 30,

  12. Slide 12: A year of strategic investment toward our FY2031 targets

    12 / 32 02 — FY2026 Results | Key Account Movements & Cash Flows A year of strategic investment toward our FY2031 targets Three accounts that moved significantly from the previous year-end, and the full-year cash flows behind them. (Unit: million yen) Key Account Movement 01 Key Account Movement 02

  13. Slide 13: The transition from the R&D phase to the production phase begins

    13 / 32 03 — FY2027 Earnings Forecast | Summary The transition from the R&D phase to the production phase begins Earnings forecast for FY2027 (October 2026 – September 2027): management indicator, its breakdown, and key profit indicators. Management Indicator Sales + Non-Operating Income 1,853 milli

  14. Slide 14: Two reasons for the operating loss

    14 / 32 03 — FY2027 Earnings Forecast | Reasons for the Operating Loss Two reasons for the operating loss Sales are forecast to rise 28.9% YoY, while operating profit moves from −314 to −350 million yen. The reasons are the accounting treatment of subsidized projects and depreciation of upfront inve

  15. Slide 15: Ordinary Profit of 158 Million Yen and EBITDA of 343 Million Yen

    15 / 32 03 — FY2027 Earnings Forecast | Ordinary Profit and EBITDA Ordinary Profit of 158 Million Yen and EBITDA of 343 Million Yen Bridge from gross profit to EBITDA (FY2027 forecast). Our EBITDA = Ordinary profit + Depreciation. (Million yen) 562 SG&A incl. R&D 184 343 467 509 158 0 Gross Profit N

  16. Slide 16: Keys: full-scale private service, 4 sample products, plant operation

    16 / 32 03 — FY2027 Earnings Forecast | FY2027 Milestones Keys: full-scale private service, 4 sample products, plant operation FY2027 sales by business, with key points for achieving the forecast and major milestones explained on a quarterly basis. FY2026 FY2027 Q1 2Q 3Q 4Q FY2028 – FY2031 Forecast

  17. Slide 17: The two-story growth engine and 19 pipelines (16 + 3 new)

    17 / 32 0 4 — M i d - t o L o n g -Te r m V i s i o n P r o g r e s s | O v e r a l l P i p e l i n e M a p The two-story growth engine and 19 pipelines (16 + 3 new) 2F Technology Package Target Pipelines Total 4PJ 4 • Woody biomass (Morisora) Bio-Fuel Energy Revolution • Paper industry materials (D

  18. Slide 18: From rice to bio-ethanol in Vietnam: a new 1F pipeline

    18 / 32 04 — Vision Progress | New Pipeline ① | Rice-Derived Bio-Ethanol Disclosed Nov. 6, 2026 From rice to bio-ethanol in Vietnam: a new 1F pipeline leading to 2F View disclosure ▶ Together with erex Co., Ltd., we are promoting the “Golden Rice Circle Project”, which produces bio-ethanol and prote

  19. Slide 19: Using every part of the rice plant: the Golden Rice Circle Project

    19 / 32 04 — Vision Progress | New Pipeline ① | Rice-Derived Bio-Ethanol Using every part of the rice plant: the Golden Rice Circle Project Ethanol and feed protein from rice; electricity from husks and straw (annual volumes, illustrative). Where GEI’s saccharification & fermentation technology cont

  20. Slide 20: Our new partner: erex, listed on the TSE Prime Market

    20 / 32 04 — Vision Progress | New Pipeline ① | Rice-Derived Bio-Ethanol Our new partner: erex, listed on the TSE Prime Market Our Golden Rice Circle Project partner is an integrated energy company engaged in biomass power generation, with operations in Vietnam. 01 erex Company Profile 02 Biomass Po

  21. Slide 21: Turning woody biomass into bio-isobutanol, a chemical feedstock

    21 / 32 0 4 — V i s i o n Pr o g r e s s | N e w P i p e l i n e ② | B i o -Is o b u t a n o l f r o m Wo o d y B i o m a s s Disclosed Oct. 30, 2026 Turning woody biomass into bio-isobutanol, a chemical feedstock View disclosure ▶ Selected for the Tokyo Metropolitan Government’s “Naphtha-Alternativ

  22. Slide 22: Contract manufacturing for agri-product production

    22 / 32 04 — Vision Progress | New Pipeline ③ | Feed & Agriculture Contract manufacturing for agri-product production Not Disclosed Details withheld per partner agreement With a domestic chemical manufacturer, we are studying contract manufacturing for commercial production of an agricultural produc

  23. Slide 23: Turning our scale-up track record into in-house production in Japan

    23 / 32 0 4 — V i s i o n P r o g r e s s | M o v e s To w a r d N e w P i p e l i n e s ( 1 / 2 ) Turning our scale-up track record into in-house production in Japan Building on the scale-up track record of our Development-Type Bio-Foundry, we are considering in-house domestic production with comme

  24. Slide 24: Harnessing the national push for more domestic manufacturing capacity

    24 / 32 0 4 — V i s i o n P r o g r e s s | M o v e s To w a r d N e w P i p e l i n e s ( 2 / 2 ) Harnessing the national push for more domestic manufacturing capacity In the bio-manufacturing section of the “Public-Private Investment Roadmap for 17 Strategic Areas,” the government sets a goal of e

  25. Slide 25: Quarterly progress of joint research and commissioned projects

    25 / 32 0 4 — V i s i o n P r o g r e s s | 1 F C a s h E n g i n e | D e v e l o p m e n t -Ty p e B i o - F o u n d r y Quarterly progress of joint research and commissioned projects Legend R&D Production Demonstration National Project Ended Private Bio-Foundry Service FY2027 key milestones (P.16)

  26. Slide 26: Quarterly progress of four cosmetic ingredient products

    26 / 32 0 4 — V i s i o n P r o g r e s s | 1 F C a s h E n g i n e | P r o d u c t i o n -Ty p e B F | C o s m e t i c I n g r e d i e n t s , e t c . Quarterly progress of four cosmetic ingredient products, etc. Leg e n d Production Tech. Verification Pilot Test Commercial Sample Production Commer

  27. Slide 27: Quarterly progress of three food products

    27 / 32 0 4 — V i s i o n P r o g r e s s | 1 F C a s h E n g i n e | P r o d u c t i o n -Ty p e B F | F o o d Quarterly progress of three food products Leg e n d Production Tech. Verification Pilot Test Commercial Sample Production Commercial Production FY2027 key milestones (P.16) ◆Now◆ Products

  28. Slide 28: Quarterly progress of three feed & agriculture products

    28 / 32 0 4 — V i s i o n P r o g r e s s | 1 F C a s h E n g i n e | P r o d u c t i o n -Ty p e B F | F e e d & A g r i c u l t u r e Quarterly progress of three feed & agriculture products Leg e n d Production Tech. Verification Pilot Test Commercial Sample Production Commercial Production FY2027

  29. Slide 29: Quarterly progress of three ongoing projects

    29 / 32 0 4 — V i s i o n P r o g r e s s | 1 F C a s h E n g i n e | Te c h n o l o g y P a c k a g e Quarterly progress of three ongoing projects Legend Lab Test Pilot Test Prep. Pilot Test Bench-Scale Test Pilot Plant Operation Semi-Commercial Plant Operation Commercial Plant Operation FY2027 key

  30. Slide 30: To Shareholders and Investors

    30 / 32 0 5 — To S h a r e h o l d e r s a n d I n v e s t o r s | I R C o m m i t m e n t To Shareholders and Investors In FY2026, our management indicator (sales + non-operating income) grew for the 9th consecutive year, results exceeded the earnings forecast, and ordinary profit was positive for

  31. Slide 31: The Future is Green.

    31 / 32 0 5 — To S h a r e h o l d e r s a n d I n v e s t o r s | C l o s i n g The Future is Green. The next chapter of GEI begins here. 01 02 03 04 05 Overturning 30+ Years of R&D Two-story Deep tech that IPO 2.0 petroleum dependence. Excellence growth engine. generates cash. Toward the cash- Sin

  32. Slide 32: Disclaimer and Forward-Looking Notes

    32 / 32 0 5 — To S h a r e h o l d e r s a n d I n v e s t o r s | D i s c l a i m e r Disclaimer and Forward-Looking Notes 1. Forward-Looking Statements The earnings forecasts and forward-looking statements in this document reflect the Company’s judgment based on information currently available and

Green Earth Institute — FY2026 Earnings Presentation on 6ix